Please login to the form below

Not currently logged in
Email:
Password:

Former FDA deputy director joins Rib-X Pharmaceuticals

Matthew Wikler appointed chief development officer of US biopharma

Matthew Wikler - Rib-XDr Matthew Wikler, a former deputy director of the US Food and Drug Administration (FDA), has been appointed chief development officer of US biopharma Rib-X Pharmaceuticals.

Dr Wikler, who takes over the role from April 30, will lead strategic development of the company's product candidates, which include delafloxacin for skin and skin structure infections.

Rib-X will benefit from Dr Wikler's years of experience in infectious diseases, including two years at the FDA where he served as deputy director, division of anti-infective drug products.

His most recent role was as president and CEO of IASO Pharma, a clinical stage biotechnology company focused on the development of antibacterial and antifungal therapeutics.

Other previous positions include senior roles at Bristol-Myers Squibb, Ortho-McNeil Pharmaceutical, the Institute for One World Health, Mpex Pharmaceuticals, Peninsula Pharmaceuticals and ViroPharma.

According to Rib-X, Dr Wikler has played a major role in the clinical development and subsequent approval of 19 antimicrobial drugs and vaccines.

“With numerous drug approvals and successful product launches under his belt and extensive experience in antibiotic drug development at both small and large companies, Dr Wikler is an excellent complement to an already exceptional team here at Rib-X,” said Mark Leuchtenberger, president and CEO of Rib-X Pharmaceuticals.

16th April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics